Pharmaceuticals

Lyra Therapeutics

Lyra Therapeutics released FY2025 annual earnings on March 31 (EST), actual revenue USD 398 K (forecast USD 738 K), actual EPS USD -18.6157 (forecast USD -25.66)

Lyra Therapeutics released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 7K (forecast USD 187K), actual EPS USD -3.9109 (forecast USD -7.14)

Lyra Therapeutics released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 391K and EPS of USD -15.3982

Lyra Therapeutics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 25K (forecast USD 154.25K), actual EPS USD -3.3849 (forecast USD -5.255)

Hanbury Brown's Rating and Target Price for Lyra Therapeutics

Hanbury Brown Rates Healthcare Sector Stocks

Lyra Therapeutics released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 183K (forecast USD 181.25K), actual EPS USD -5.5144 (forecast USD -5.5266)

Lyra Therapeutics released FY2025 Semi-Annual Earnings on August 12 EST, with actual revenue of USD 366 K and EPS of USD -12.0001

Lyra Therapeutics Inc. CFO Disposes of Common Stock

Lyra Therapeutics Inc to issue up to $15 million in stock

HC Wainwright Maintains Lyra Therapeutics Rating, Raises Target Price

Lyra Therapeutics Short Position Ratio Rises 171.37%

Lyra Therapeutics Announces Positive Results for Chronic Sinusitis Phase III Trial

Lyra Therapeutics Annual Meeting Approves Multiple Proposals

Lyra Therapeutics Expecting Q2 Loss of 14 Cents Per Share

Lyra Therapeutics released FY2025 Q1 earnings on May 6 (EST), actual revenue USD 183 K (forecast USD 160 K), actual EPS USD -6.4988 (forecast USD -6.8333)

LYR 210 Phase 3 Trial Results for Chronic Rhinosinusitis Expected to be Released

Lyra Therapeutics Inc projects Q1 2025 loss of 14 cents per share

Lyra Therapeutics released FY2024 Q4 earnings on March 13 (EST), actual revenue USD 209K (forecast USD 206K), actual EPS USD -8.3794 (forecast USD -6)

Lyra Therapeutics released FY2024 earnings on March 13 (EST), actual revenue USD 1.534 M (forecast USD 1.524 M), actual EPS USD -71.7474 (forecast USD -66.375)

Visionary

Sky Quarry

TMD Energy

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Semilux

Cocrystal Pharma

Sidus Space

Swarmer

Franklin Covey

Biodexa Pharmaceuticals

Eli Lilly

ROCHE HOLDINGS AG

Roche

AstraZeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Otsuka Pharmaceutical

Daiichi Sankyo

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Lyra Therapeutics(LYRA.US)

Lyra Therapeutics Stock Performance Chart